Current Investments

Eidos Therapeutics, Inc. (NASDAQ: EIDX) is developing a novel drug to treat all forms of Transthyretin (TTR) amyloidosis, a condition characterized by toxic amyloid aggregates in the heart and peripheral nerves. The lead candidate, AG10 is an orally-administered, small molecule designed to mimic a naturally-occurring genetic rescue mutation that protects high-risk individuals from developing TTR amyloidosis.
Headquarters: San Francisco, California
Website: http://eidostx.com/

Essential Medical es una compañía de tecnología médica que desarrolla dispositivos de cierre vascular para punciones femorales posteriores a los procedimientos de cateterismo cardíaco. Estos procedimientos cardíaco, como TAVR y EVAR, son algunos de los segmentos que destacan la necesidad para proporcionar soluciones rápida, fácil y sin complicaciones para el cierre vascular.
Headquarters: Malvern, Pennsylvania
Website: http://www.essmedclosure.com/

GTx, Inc. (NASDAQ: GTXI) is a clinical stage biotechnology company focused on developing small molecules that selectively modulate the effects of certain hormones produced by the body. The company is moving forward selective androgen receptor modulators, also referred to as SARMs, to potentially treat a number of diseases such as stress urinary incontinence.
Headquarters: Memphis, Tennessee
Website: http://www.gtxinc.com/

Inspire Medical Systems, Inc. (NYSE: INSP) developed the world's first fully implantable neurostimulation system for treatment of obstructive sleep apnea. The device works by opening up the upper airway in synchrony with patient's breathing during sleep through gentle stimulation of the key airway muscles. It offers a safe, effective and minimally invasive alternative to millions of patients who have failed or are intolerant of Continuous Positive Airway Pressure (CPAP).
Headquarters: Maple Grove, Minnesota
Website: https://www.inspiresleep.com/

Iterum Therapeutics plc (NASDAQ:ITRM) is dedicated to developing differentiated anti-infectives aimed at combatting multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound with oral and IV formulations for the treatment of uncomplicated and complicated urinary tract infection and complicated intra-abdominal infection.
Headquarters: Dublin, Ireland
Website: http://www.iterumtx.com

KEW Group Inc. (KEW) está revolucionando el tratamiento de cáncer, proporcionándole a oncólogos con acceso a pruebas genómicas tratamientos personalizados para cada paciente. Los productos y las soluciones de KEW Group están diseñados para proporcionar una terapia contra el cáncer personalizada, dándoles a oncólogos la opción de tomar decisiones de tratamiento más precisas que las que generalmente están siendo ofrecidas.
Headquarters: Cambridge, Massachusetts
Website: www.kewgroup.com

MEI Pharma, Inc. (NASDAQ: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The company’s diverse portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The clinical development pipeline also includes ME-401, a highly selective, oral PI3K delta inhibitor, voruciclib, an oral, selective CDK inhibitor, and ME-344, a novel mitochondrial inhibitor.
Headquarters: San Diego, California
Website: http://www.meipharma.com

MIACH Orthopaedics, Inc. is a medical technology company developing innovative bio-engineered surgical implants for connective tissue repair. The company’s initial focus is on the Bridge-Enhanced® ACL Repair (BEAR®) technology as a viable high performance alternative to conventional ACL reconstruction using grafts. The BEAR technology was pioneered by Martha Murray, M.D., at the Boston Children’s Hospital Department of Orthopaedic Surgery.
Headquarters: Boston, Massachusetts
Website:

Selecta Biosciences, Inc. (NASDAQ: SELB) is a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses. Selecta is combining its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. SEL-212, the company’s lead candidate is being developed to treat severe gout patients.
Headquarters: Watertown, Massachusetts
Website: http://selectabio.com/

Teligent (NASDAQ: TLGT) formula, desarrolla, fabrica y envasa cremas y otros productos tópicos para la industria farmacéutica y cosmética en los Estados Unidos. La compañía también vende y produce un portafolio propietario de farmacéuticos tópicos genéricos que son bioequivalentes a sus homólogos de marca.
Headquarters: Buena, New Jersey
Website: www.teligent.com

Zosano Pharma (NASDAQ: ZSAN) has developed a proprietary transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications. Company’s lead program ADAM Zolmitriptan (M207) is a transdermal formulation of zolmitriptan designed to provide rapid relief of migraine symptoms in a discreet and simple manner.
Headquarters: Fremont, California
Website: http://www.zosanopharma.com/